How To Build The Future: Max Hodak

Quick Overview

Max Hodak, co-founder of Neuralink and founder/CEO of Science, predicts that within 10 to 20 years, brain-computer interfaces (BCIs) will be able to restore significant functionality to people with severe disabilities, such as those with blindness or paralysis, by bypassing damaged neural pathways and directly stimulating the remaining neurons or sensory organs.

Key Points: Hodak believes it is very possible that the first people to live to 1000 years old are alive right now, suggesting radical life extension is nearing. Science recently announced that over 40 people have received their first BCI treatments, which are small 2mm x 2mm silicon chips implanted under the retina. The BCI device works by projecting an image onto the retina via a laser projector, which then excites the photoreceptor cells (rods and cones) that are still alive. The technology allows for restoration of vision by bypassing dead rods and cones, and Hodak is also excited about the potential for motor control restoration for paralyzed individuals. Hodak contrasts the drug discovery approach with the neuroengineering approach, noting that the latter can be much more powerful for treating conditions like macular degeneration and paralysis. The major challenge for BCI development is creating a system that can process the vast amount of information flowing from the brain (estimated at 40 bits per second) in a way that is intuitive and doesn't overwhelm the patient. Hodak notes that the ethical implications of highly advanced, conscious AI systems are something that must be considered, but he believes the immediate focus should be on treating the most disabled populations.

Context: This interview features Max Hodak, co-founder of Neuralink and the Founder & CEO of Science, speaking with Garry Tan, President & CEO of Y Combinator, on the 'How To Build The Future' podcast. The discussion centers on the advancements and ethical considerations surrounding brain-computer interfaces (BCIs), specifically referencing Science's work with their PRIMA vision restoration technology, which involves implanting micro-electrode arrays to stimulate the retina.